CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
961-975 of 1225
Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
Jyoti Patel, MD
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®Treatment Intensification in HR+/HER2- EBC: Who and When?
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®Maximizing Adherence and Persistence via Patient Engagement
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
Nadia Harbeck, MD, PhD
- advertisement
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
- MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Interprofessional Coordination of Adverse Event Management
MinuteCE®Interprofessional Coordination of Adverse Event Management
Nadia Harbeck, MD, PhD
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®Recent updates from adjuvant trials in HR+/HER2- EBC
Nadia Harbeck, MD, PhD
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
- advertisement
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
CME/CEImplementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Christina Economides, MD
Brian Howard, MD
David N. Kenigsberg, MD, FACC
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
CME/CEWarm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
Caroline Piatek, MD
Irina Murakhovskaya, MD
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Shubham Pant, MD, MBBS